Poseida Therapeutics (NASDAQ:PSTX) Stock Rating Reaffirmed by HC Wainwright

Poseida Therapeutics (NASDAQ:PSTX)‘s stock had its “buy” rating reiterated by equities researchers at HC Wainwright in a research report issued on Monday, Benzinga reports. They currently have a $20.00 price target on the stock.

Poseida Therapeutics Price Performance

Poseida Therapeutics stock opened at $2.02 on Monday. Poseida Therapeutics has a 1 year low of $1.54 and a 1 year high of $4.27. The firm has a 50 day moving average price of $3.20 and a 200 day moving average price of $2.95. The company has a market cap of $194.91 million, a price-to-earnings ratio of -1.45 and a beta of 0.36. The company has a debt-to-equity ratio of 0.56, a quick ratio of 3.18 and a current ratio of 3.18.

Poseida Therapeutics (NASDAQ:PSTX) last released its earnings results on Thursday, March 7th. The company reported ($0.27) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.36) by $0.09. Poseida Therapeutics had a negative net margin of 190.76% and a negative return on equity of 94.90%. The firm had revenue of $25.00 million during the quarter, compared to the consensus estimate of $12.50 million. Sell-side analysts predict that Poseida Therapeutics will post -1.77 earnings per share for the current year.

Institutional Investors Weigh In On Poseida Therapeutics

Institutional investors have recently bought and sold shares of the stock. State of Wyoming purchased a new stake in Poseida Therapeutics in the fourth quarter valued at approximately $38,000. Susquehanna Fundamental Investments LLC acquired a new position in Poseida Therapeutics during the fourth quarter valued at approximately $55,000. Dynamic Technology Lab Private Ltd acquired a new position in Poseida Therapeutics during the fourth quarter valued at approximately $36,000. Tower Research Capital LLC TRC lifted its position in Poseida Therapeutics by 110.5% during the fourth quarter. Tower Research Capital LLC TRC now owns 10,679 shares of the company’s stock valued at $36,000 after buying an additional 5,606 shares in the last quarter. Finally, Prelude Capital Management LLC acquired a new position in Poseida Therapeutics during the first quarter valued at approximately $50,000. 46.87% of the stock is currently owned by hedge funds and other institutional investors.

About Poseida Therapeutics

Poseida Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company's development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications.